MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS…
SHANGHAI, China, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a…
Virtual Event to be held on November 29, 2023 at 4:15 p.m. ETLOS ANGELES, Nov. 22, 2023 (GLOBE NEWSWIRE) --…
NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG-KONG, JAPAN, CANADA, SWITZERLAND,…
Data presented at the Society of NeuroOncology (SNO) 28th Annual MeetingBerubicin currently being evaluated in an ongoing potentially pivotal study…
MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies…
SYDNEY, AUSTRALIA, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage…
Grant of Its Newest U.S. Patent Expands Anavex’s Compounds Intellectual Property PortfolioNEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Anavex…
WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical…
PRESS RELEASE - 22 November 2023, 10:00 CET BIOCARTIS HOLDINGS INC. RECAPITALIZATION COMPLETED AND PRODUCT PORTFOLIO EXPANSION The recapitalization of…